Results 221 to 230 of about 14,572,147 (286)

Baseline Body Mass Index Category and Incident Treated Hypertension in Australian Men: A Linked Prospective Cohort Study Using PBS/MBS Data

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Kaplan–Meier hypertension‐free survival by baseline body mass index category, primary adult cohort (men aged ≥ 18 years, n = 12,742). Time since baseline in years is plotted on the horizontal axis and the probability of remaining free of treated hypertension is plotted on the vertical axis. Numbers at risk are shown beneath the plot.
Ebenezer Afrifa‐Yamoah
wiley   +1 more source

Green and sustainable synthesis of magnetite from copper slag via citrate complexation for methylene blue dye removal from water

open access: yesThe Canadian Journal of Chemical Engineering, EarlyView.
Abstract This study proposes a novel, green, and sustainable method for synthesizing magnetic iron oxides from metallurgical copper slag (CS), leveraging its iron content as a valuable resource. Iron was extracted via acid leaching using edible citric acid (ECA), forming a citrate–iron complex (CSL), which was subsequently thermally decomposed at 300°C
Melisa Portilla‐Sangabriel   +4 more
wiley   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary   +59 more
wiley   +1 more source

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy